These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28083710)

  • 1. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
    Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
    Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].
    Zhang P; Zeng X; Gao J; Liu W; Shuai X; Liu K; Liu X; Cai M; Cai K; Wang G; Tao K
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1290-1295. PubMed ID: 27928802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
    Tang S; Yin Y; Shen C; Chen J; Yin X; Zhang B; Yao Y; Yang J; Chen Z
    World J Surg Oncol; 2017 Apr; 15(1):79. PubMed ID: 28399894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
    Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y; Hao H; Guo L; Yang G; Zhang X
    Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
    JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
    Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
    Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY
    J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
    Sutton TL; Billingsley KG; Johnson AJ; Corless CL; Blanke CD; Heinrich MC; Mayo SC
    J Surg Oncol; 2024 Jul; 130(1):40-46. PubMed ID: 38924626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prognosis of 108 patients with high-risk gastrointestinal stromal tumor].
    Lei C; Liu L; Wang Q; Wang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1300-1304. PubMed ID: 27928804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
    Wu X; Li J; Xu W; Gao J; Li Y; Shen L
    Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
    Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative imatinib treatment in patients with advanced gastrointestinal stromal tumors: patient experiences and systematic review of 563 patients.
    Xu J; Ling TL; Wang M; Zhao WY; Cao H
    Int Surg; 2015 May; 100(5):860-9. PubMed ID: 26011207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
    Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY
    Ann Oncol; 2021 Apr; 32(4):533-541. PubMed ID: 33482247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].
    Li SX; Li ZY; Zhang LH; Bu ZD; Wu AW; Wu XJ; Zong XL; Shan F; Ji X; Ji JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):226-9. PubMed ID: 23536340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
    Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
    Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.